Novo Nordisk spelled out how it will try to catch up with the extraordinary demand for its GLP-1 drugs, underscoring its rationale for its in-house API production and strategic fill ...

Eli Lilly will pay up to $1.925 billion in cash for weight loss drugmaker Versanis, marking the Big Pharma’s fourth acquisition this summer after deals for DICE Therapeutics, Sigilon and ...

French biotech Smart Immune has raised more than half of its roughly €50 million ($54 million) target in an ongoing Series A round, with an eye to completing Phase I ...

Gene therapy startup enGene became a public biotech on Wednesday after completing its combination with Forbion European Acquisition, a blank check company formed in 2021. The Montreal and ...

CVS Health is shut­ting down the clin­i­cal tri­als busi­ness that it launched just two years ago, part of an ef­fort to fo­cus on its core … ...

The next generation of Operation Warp Speed is coming soon, and this time it's going to take aim at rare diseases, Peter Marks, the director of the FDA's Center for ...

The FDA is hoping its latest solution will stave off the continued shortage of cisplatin, a key drug used in treating several types of cancer. Beginning ...

Endpoints Health Tech newsletter wins SABEW award for business journalism, recognized for coverage of healthcare industry issues including weight loss drugs and value-based care.

Tech, com­merce-fo­cused in­vestor un­veils $500M bet on health­care ...

Vertex sued the federal government on Monday in an effort to expand its fertility support program to certain patients taking its new gene therapy for sickle cell disease and transfusion ...

Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3Kα inhibitor through Phase Ia and has named Nassim Usman as its new president and ...

Plus, news about Oruka Therapeutics, Centessa, Takeda, Innate Pharma and Liquidia: GSK’s mRNA flu vaccine succeeds against both strains in Phase 2: The pharma company ...